Last updated on April 16, 2014 at 21:24 EDT

Medicago to Present at the 2012 BioEquity Europe Conference

May 10, 2012

QUEBEC CITY, May 10, 2012 /PRNewswire/ – Medicago Inc. (TSX: MDG), a
biopharmaceutical company focused on developing highly effective and
competitive vaccines based on proprietary manufacturing technologies
and Virus-Like Particles (VLPs), today announced that Mr. Mike Wanner,
Executive Vice President, Operations, will be presenting at the 13th
Annual BioEquity Europe Conference. The conference is being held May
15-16, 2012, at the Frankfurt Marriott Hotel in Frankfurt, Germany. 
Mr. Wanner is scheduled to present on May 16th, 2012, at 11 a.m.
Central European Time.

About the BioEquity Europe Conference
The 13th annual BioEquity Europe Conference is the premier venue for
biopharma companies looking to attract capital and expand their
business development efforts. The 2012 conference is set to offer an
unparalleled showcase of investment opportunities at a critical time
for the life sciences. The conference brings together professional
investors, bankers, analysts and pharma business development and
licensing professionals with leading public and late-stage private
companies. Additional information is available at www.biocentury.com/conferences

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of
infectious diseases worldwide. The Company is committed to providing
highly effective and competitive vaccines and therapeutic proteins
based on its proprietary VLP and manufacturing technologies. Medicago
is a worldwide leader in the development of VLP vaccines using a
transient expression system which produces recombinant vaccine antigens
in plants. This technology has potential to offer more potent vaccines
with speed and cost advantages over competitive technologies, enabling
the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a
pandemic strain. This production time frame has the potential to allow
vaccination of the population before the first wave of a pandemic, and
supply large volumes of vaccine antigens to the world market. Medicago
also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make
a significant difference. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements
This news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and uncertainties
associated with Medicago’s business and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “anticipate”, “believe”,
“plan”, “estimate”, “expect”, “intend”, and similar expressions to the
extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from current
expectations, including the matters discussed under “Risk Factors and
Uncertainties” in Medicago’s Annual Information Form filed on March 29,
2012, with the regulatory authorities. Medicago assumes no obligation
to update the forward-looking statements, or to update the reasons why
actual results could differ from those reflected in the forward-looking

SOURCE Medicago Inc.

Source: PR Newswire